[Expression of CD19 and CD56 in AML Patients with RUNX1-RUNX1T1 Mutation and Its Clinical Significance].
To investigate the clinical significance of RUNX1-RUNX1T1 expression level in bone marrow of patients with acute non-M3 myeloid leukemia (AML non-M3), and to understand the biological characteristics of RUNX1-RUNX1T1 positive AML expressing lymphoid antigens CD19, CD56 and its effect on the initially induced remission rate and prognosis. The expression level of RUNX1-RUNX1T1 in bone marrow of 200 patients with newly diagnosed AML (non-M3) was detected by real-time fluorescent Q-PCR, the expression level of lymphoid antigens was detected by flow cytometry, and the relationship of the initially induced remission rate (CR1) with the overall survival (OS) rate was analyzed, the CR1 and OS differences also were analyzed between CD56+ and CD56- patients as well as CD19+ and CD17- patients in RUNX1-RUNX1T1 positive patients with AML. The CD56+ patients at the initial diagnosis had lower CR1(P<0.05) in RUNX1-RUNX1T1 positive AML patients, the CR1 of CD19+ patients was higher than that in CD19- patients at the initial diagnosis (P<0.05). The OS of CD56+ patients was significantly high in comparison with CD56- patients (P<0.05), while the OS between CD19+ patients and CD19- patients was not significantly different. The bone marrow CD56+ in RUNX1-RUNX1T1 positive AML patients suggests poor prognosis. The CD19+ only correlates with CR1, but does not with OS.